PMEL and melanoma: These patients were treated with ipilimumab combined with DCs electroporated with CD40L, CD70, and constitutively activated TLR-4 encoding mRNA and one of 4 melanoma-associated antigens (MAGE-A3, MAGE-C2, tyrosinase, or gp100) fused to an HLA-class II targeting signal (131).